Sudershan Arora and India - Free people check

(1 - 18 from 22

)

R&D gives India its big boost in the tech world

www.bbc.co.uk

[BBC News] - Dr Sudershan Arora, president of R&D at Ranbaxy says: "The country ... has a large pool of treatment-naive population with diverse disease patterns, [which make it easy for] recruitment [for research]." "These are some of the inherent strengths that

India's first anti-malaria drug is among the 'best' | Deccan Herald

www.deccanherald.com

The first indigenously made anti-malarial drug made its debut on Wednesday, arming doctors with one more weapon to fight the disease that kills thousands of...

2nd UK-India MedChem Congress

www.rsc.org

Dr Anthony Addlagatta, IICT, India Dr Sudershan Arora, Ranbaxy Research, India Dr Clifton E Barry III, National Institute of Allergy and Infectious Diseases, USA

Ranbaxy Laboratories Limited : RANBAXY HONOURS 5 OUTSTANDING...

www.marketscreener.com

Also confers a Special Award in the field of Public Health Gurgaon, India, February 27, Ranbaxy Science...

Kailash overseas

www.gmdu.net

We are traders and we import goods from other countries and sell them respectively in India.we are having our company in Delhi dealings with electronic goods...

LinkedIn: Sudershan Arora - Vice President - Development - Inca ...

Sudershan Arora Vice President - Development at Inca Informatics Pvt Limited Noida, Uttar Pradesh, India112 connections Join to Connect Inca Informatics Pvt Limited Indian Institute of Technology,...

LinkedIn: sudershan arora | LinkedIn

View sudershan arora's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like sudershan arora discover ...

LinkedIn: Sudershan Arora - India | LinkedIn

Sudershan Arora. Experience: Vice President, Quark Media House; Vice President, Quark; Vice President, Quark Media House India. Looked after R & D, Quality Management ...

Ranbaxy boosts presence in Africa with malaria drug

www.prokerala.com

"It is among the best options available today," said Sudershan Arora, president, research and development (R&D), of the Indian unit of Japanese Daiichi Sankyo company. The new drug, Aurora said, was "developed as a fixed ...

GARP: India - Center for Disease Dynamics cddep

cddep.org

Sudershan Arora, Ranbaxy Laboratories Ltd., Gurgaon Preena Bhalla, Director, Professor & Head of Department of Microbiology, Maulana Azad Medical College, ... › ... › GARP Network

Efficacy and safety of fixed dose combination of arterolane maleate...

malariajournal.biomedcentral.com

by OA Toure · · Cited by 23 — Sudershan Arora. CDM and Biostatistics, Ranbaxy Laboratories Ltd, Gurgaon, Haryana, India. Arjun Roy. Medical Global Marketing Corporate ... › articles

R&D gives India its big boost in the tech world « Dr. TGI Fernando

tgifernando.wordpress.com

Dr Sudershan Arora, president of R&D at Ranbaxy says: “The country … has a large pool of treatment-naive population with diverse disease patterns, [which make it easy for] recruitment [for research].” “These are some of the ...

India's first anti-malaria drug is among the 'best' – Jaya Bharat ...

odiasamachar.wordpress.com

It is among the best options available today,” said Sudershan Arora, president (Research and Development) at Ranbaxy. “Malaria is highly endemic in 17 states and mostly affects the poor. The company should see the drug is ...

Sudershan Arora | LinkedIn

www.linkedin.com

Sudershan Arora. Vice President - Corporate Affairs at Inca Informatics Pvt Ltd. Location Noida Area, India Industry Computer Software

Ranbaxy Unveils Synriam: India's First Anti-Malarial Drug | Asian ...

www.asianscientist.com

Synriam, which will be marketed first in India, is developed as a fixed dose combination consisting of arterolane maleate 150 mg and piperaquine phosphate 750 mg, explained Dr. Sudershan Arora, President-R&D, Ranbaxy.